Q-omics provides the consensus-scored CHP1P2 profile across patient tissues and cancer cell-line models. CHP1P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CHP1P2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CHP1P2 RNA expression shows 19,087 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where CHP1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHP1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHP1P2 survival associations across molecular data types. CHP1P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHP1P2 RNA expression–survival associations across cancer types. High CHP1P2 expression shows unfavorable associations in MESO, STAD, LGG and SARC, but favorable associations in READ and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CHP1P2 RNA expression.
This table summarizes CHP1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CHP1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHP1P2 shows higher tumor expression in HNSC, THCA, KIRC, UCEC, STAD and BLCA. The HNSC box plot shows higher CHP1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.756, t-test p < 0.001).
This table shows molecular features associated with CHP1P2 in patient tissues and cancer cell lines. In patient samples, CHP1P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHP1P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
